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Abstract: The bone marrow (BM) microenvironment plays an important role in supporting
proliferation, survival and drug resistance of Multiple Myeloma (MM) cells. MM cells adhere
to bone marrow stromal cells leading to the activation of tumour-promoting signaling pathways.
Activation of the NFκB pathway, in particular, is central to the pathogenesis of MM. Tumour necrosis
factor receptor-associated factor 6 (TRAF6) is a key mediator of NFκB activation and has previously
been highlighted as a potential therapeutic target in MM. Here, we demonstrate that adherence of
MM cell lines to stromal cells results in a reciprocal increase in TRAF6 expression. Knockdown of
TRAF6 expression attenuates the ability of MM cells to bind to stromal cells and this is associated with
a decrease in NFκB-induced expression of the adhesion molecules ICAM1 and VCAM1. Finally, we
show that knockdown of TRAF6 sensitizes MM cells to treatment with bortezomib when co-cultured
with stromal cells. Inhibiting TRAF6 represents a promising strategy to target MM cells in the
BM microenvironment.
Keywords: Multiple Myeloma; TRAF6; BMSCs
1. Introduction
Multiple Myeloma (MM) is characterised by the proliferation of malignant plasma cells in
the bone marrow, resulting in the excessive production of monoclonal protein in the serum and
urine. MM manifests clinically with osteolytic bone disease, anaemia, immunodeficiency and renal
insufficiency. Over the past 15 years, response rates and overall survival have significantly improved
with the introduction of proteasome inhibitors [1], immunomodulatory agents [2], and more recently
monoclonal antibodies [3], to the clinic. However, despite these improvements MM largely remains an
incurable disease and acquired drug resistance and disease relapse present a clinical challenge [4,5].
The bone marrow (BM) microenvironment comprising bone marrow stromal cells (BMSCs),
immune cells, osteoclasts, osteoblasts and extracellular matrix, plays a critical role in disease
progression. MM cells home to and adhere to BMSCs, leading to the production of tumour-promoting
cytokines and the activation of key signalling pathways, such as nuclear factor kappa B (NFκB), in both
MM cells and BMSCs [6,7]. This interaction promotes MM cell proliferation, migration, survival and
drug resistance. Through the upregulation of interleukin (IL)-6 and receptor activator of NFκB ligand
(RANKL), BMSC–MM interactions also promote the differentiation and proliferation of osteoclasts
which lead to bone resorption and further promote the growth of MM cells [8,9], forming a vicious
cycle of bone destruction and MM cell proliferation. It is important, therefore, to develop novel
therapeutic approaches which act not only on MM cells but also on the protective microenvironment.
Tumour Necrosis Factor Receptor-Associated Factor 6 (TRAF6) is an E3 ligase that functions
primarily to activate downstream signalling cascades in a degradation-independent manner [10]. Upon
ligand binding, TRAF6 is recruited to receptor complexes and catalyses K63-linked polyubiquitination
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on itself and its target proteins [11]. TRAF6-mediated polyubiquitination initiates signalling cascades
that lead to the activation of NFκB, MAPK and PI3K [12–14]. CD40L, IL-1, IL-17 and RANKL, all
of which are upregulated in the BM microenvironment, can bind to TRAF6 receptors and activate
downstream signalling [15–18]. It is not surprising therefore, that upregulated TRAF6 expression
is reported in MM [19]. Furthermore, it has previously been demonstrated that TRAF6 silencing
inhibits MM cell proliferation in cell lines and primary cells and inhibits osteoclast formation and
bone resorption [19,20]. In this study, we sought to investigate the effect of TRAF6 silencing on
MM–BMSC interactions.
2. Materials and Methods
2.1. Cell Lines and Reagents
U266, KMS-11, HS-5 and Phoenix GP cells were cultured in a humidified incubator at 37 ◦C and
5% CO2 in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin
and 100 µg/mL streptomycin (Fisher Scientific, Loughborough, UK). Bortezomib was purchased from
Selleckchem (Absource Diagnosticsm Munchen, Germany), reconstituted in DMSO and stored at
−20 ◦C.
2.2. Retroviral Transfection
Retroviral particles expressing an shRNA against TRAF6 were generated by transfection of a
pRSC vector together with pMD2.G into Phoenix GP cells. The shRNA sequence is shown below. Cells
infected with a vector expressing non-targeting control (NTC) shRNA were used as controls. Cells
were selected for in 0.5 µg/mL puromycin (Sigma-Aldrich, Dorset, UK) 48 h post-transduction.
Sequence: shTRAF6 GAGAACACCCAGTCACACA
2.3. Stromal Cell Co-Culture
Stromal cell co-cultures were set up using either the human stromal cell line HS-5 or BMSCs
from MM patients. Patient BMSCs were isolated from BM aspirates as previously described [21]. MM
cell lines or stromal cells were cultured either alone or together at a 1:5 (BMSC/MM) ratio and cell
proliferation was measured using CyQUANT® Direct cell proliferation assay, as per the manufacturer’s
instructions (ThermoFisher Scientific, Loughborough, UK). If required, separation of myeloma cells
from the HS-5 stromal cells was performed by selection with anti-CD138 magnetic cell separation
micro beads using the AutoMACS system (Miltenyi Biotech, Bergisch Gladbach, Germany) according
to the manufacturer’s instructions.
2.4. Adhesion Assay
HS-5 stromal cells and stromal cells obtained from MM patients were seeded at 1 × 104 in 100 µL
per well in a flat-bottom 96-well optical plate and cultured overnight to establish an adherent monolayer.
MM cell lines were incubated with Calcein-AM (Abcam, Cambridge, UK) for 1 h, added to stromal cells
at a concentration of 5 × 105/mL and allowed to adhere for 2 h. Plates were gently inverted to remove
media and washed 3 times with RPMI 1640 medium to remove non-adherent cells. Fluorescence was
measured at excitation 485 nm/emission 520 nm using a Tecan Genios microplate reader.
2.5. Real-Time PCR
Total RNA was extracted from cells using ReliaPrep™ RNA Cell Miniprep System (Promega,
Wisconsin, UK). An amount of 500 ng RNA was converted to cDNA using MMLV (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. The primers for TRAF6, VCAM1, ICAM1 and
18S were designed against Genbank published sequences in association with Primer Express (Applied
Biosystems) and were obtained from Eurofins MWG Operon (Huntsville, AL, USA). Amplification for
primers was performed using the FastStart Universal SYBR Green master mix (Roche Applied Science,
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Mannheim, Germany). Reactions were performed on a 7900HT fast Real-Time PCR system using ABI
sequence detection software v2.3 (Applied Biosystems, Warrington, UK). Values were normalized to
the endogenous 18S rRNA control and the relative mRNA fold changes were quantified using the
2−∆∆Ct method.
Primers:
ICAM1
Forward: CAGGGAACTGGTCAGGAACC
Reverse: ATCCTCAGCCCTAAGGAGCA
VCAM1
Forward: CGTCTTGGTCAGCCCTTCCT
Reverse: ACATTCATATACTCCCGCATCCTTC
TRAF6
Forward: TTCAGTACTTTTGGTTGCCATGA
Reverse: TGTGACTGGGTGTTCTCTTGTAGGT
2.6. Western Blotting
Cells were harvested and lysed in radioimmunoprecipitation (RIPA) buffer containing protease
and phosphatase inhibitors. An amount of 20 µg of protein for each sample was denatured in LDS
sample buffer (Invitrogen Ltd., Paisley, UK) at 95 ◦C for 5 min and resolved by SDS-PAGE on 10%
Bis-Tris gels (Invitrogen Ltd., Paisley, UK). The protein was then transferred to a polyvinylidene
fluoride (PVDF) membrane. Immunoblotting was carried out using antibodies against GAPDH
(Abcam, Cambridge, UK), TRAF6, Total/p-IKKα/β, Pan-Actin, Total/p- TRAF6, Total/p-IKα,
Total/p-p65 (Cell Signaling Technology, Hertfordshire, UK) and secondary antibodies anti-mouse and
anti-rabbit (DAKO, Cambridgeshire, UK). Blots were probed with WesternBright™ ECL horseradish
peroxidase (HRP) substrate (Advansta, Labtech, East Sussex, UK) for visualisation of protein.
2.7. Statistical Analysis
Data was processed using Prism v.6 (GraphPad Software, San Diego, CA, USA). Student’s t-test
was used to derive statistical significance.
3. Results
3.1. TRAF6 Expression Is Enhanced Upon Adherence of MM Cells to BMSCs
BMSCs play an important role in the survival of MM cells and contribute to cell adhesion-mediated
drug resistance. Huang and colleagues recently demonstrated that BMSCs induce the expression of
TRAF6 in MM cell lines [22]. To investigate whether TRAF6 expression is similarly affected in BMSCs,
we co-cultured KMS-11 and U266 cell lines with the human stromal cell line HS-5. After 24 h, MM and
HS-5 co-cultures were separated by CD138+ selection of MM cell lines and TRAF6 protein expression
was evaluated in cell lines, HS-5 cells, and matched cells that had been cultured in isolation. TRAF6
protein levels significantly increased both in MM cell lines (Figure 1A, p ≤ 0.05) and BMSCs (Figure 1B p
≤ 0.02) that had been co-cultured compared to cells that had been grown in single cultures, suggesting
that TRAF6 is activated by BMSC–MM interactions. We next looked at the effect of TRAF6 silencing
on the proliferation of MM cell lines cultured in the presence and absence of HS-5 cells. In general,
TRAF6 knockdown cells (shTRAF6) grew significantly more slowly than their control counterparts
(NTC—non-targeting control) (Figure 1C,D; p ≤ 0.04, 72 h; not significant for KMS-11 single cultures).
Co-culture with HS-5 cells increased the growth of both control and TRAF6 knockdown cell lines, however,
proliferation of both KMS-11 and U266 TRAF6 knockdown cells was most significantly reduced in stromal
cell co-cultures compared to those grown in the absence of HS-5 cells (p ≤ 0.04). To investigate the
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upstream molecules important for TRAF6 activation in MM cells, we looked at the effect of blocking
CD40 and RANKL activation of TRAF6 using inhibitory peptides, however, inhibition of either of these
interactions alone had no significant effect on MM cell growth (data not shown).
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Figure 1. Tumo r necrosis factor receptor-associated factor 6 (TRAF6) expression is enhanced
in bo e marrow stromal cell (BMSC) co-cultures: (A) TRAF6 protein expression in KMS-11 and
U266 cells culture on their own or in c -culture with HS-5 cells; optical density normalized to
GAPDH and expressed as a percentage of KMS-11 or U266 cells cultured alone (n = 3). (B) TRAF6
protein expression in HS-5 cells cultured n their own or in co-cultures with KMS-11 or U266 cells;
optical density normalized to GAPDH and expressed as a percentage of HS-5 cells cultured alone
(n = 3). (C) Proliferation of KMS-11 cells transduced with on-targeting contr l (NTC) shRNA or
shRNA targeting TRAF6 (shTRAF6), cultured in isolation (left panel) or in co-culture with HS-5
cells (right panel), n = 4; (D) Proliferation of U266 cells transduced with NTC shRNA or shRNA
targeting TRAF6, cultured in isolation (left panel) or in co-culture with HS-5 cells (right panel), n = 4.
* p ≤ 0.05, ** p ≤ 0.01.
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3.2. TRAF6 Knockdown Impairs Adhesion to BMSCs
Adhesion of MM cells to BMSCs stimulates NFκB transcription of adhesion molecules [23].
As TRAF6 is a key modulator of NFκB activation, we speculated that TRAF6 silencing could alter
the adherent properties of MM cells. KMS-11 is a semi-adherent cell line that grows in tissue culture
flasks as a mixture of adherent and non-adherent cells. Knockdown of TRAF6 in KMS-11 cells resulted
in a significant decrease in the proportion of adherent cells compared to control cells (Figure 2A,
p = 0.02). We next investigated the ability of TRAF6 knockdown cells to adhere to BMSCs using
a fluorescence-based adhesion assay. KMS-11 and U266 cells were labelled with Calcein-AM and
adhesion to both HS-5 and BMSCs from MM patients was measured. TRAF6 knockdown cells exhibited
a significant reduction in adhesion to both HS-5 and patient BMSCs (Figure 2B,C, p ≤ 0.05).
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Figure 2. TRAF6 knockdown disrupts adhesion to BMSCs: (A) Proportion of suspension and adherent
cells in KMS-11 TRAF6 knockdown cells (shTRAF6) compared to non-targeting control (NTC) cells;
(B) Effect of TRAF6 knockdown on the ability of KMS-11 and U266 cells to adhere to HS-5 cells; (C) Effect
of TRAF6 knockdown on the ability of KMS-11 and U266 cells to adhere to BMSCs from MM patients.
The data is presented as mean (± st dev) of three independent experiments. * p ≤ 0.05, ** p ≤ 0.01.
3.3. Knockdown of TRAF6 Inhibits NFκB Signalling
TRAF6 has previously been implicated in the regulation of NFκB activation in MM cells [19,20,22].
As NFκB is known to promote the expression of a number of adhesion molecules, we looked at
the effect of TRAF6 silencing on NFκB pathway activation in MM cells and on the expression of
NFκB target genes, intracellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1
(VCAM1). Knockdown of TRAF6 in both cell lines led to a striking decrease in the phosphorylation
of inhibitor of NFκB kinase α/β (IKK α/β), IκB α and p65 (Figure 3A) and this was accompanied
with a signifi ant decrease in the mRNA expression of the adhes on molecules ICAM1 and VCAM1
(Figure 3B,C, p ≤ 0.04). Furthermore, the expression of TRAF6, and of ICAM1 and VCAM1, was also
decreased in HS-5 cells that were c -cultured with shTRAF6 KMS-11 an U266 cells (Figure 3D,E,
p ≤ 0.03).
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Figure 3. TRAF6 knockdown inhibits NFκB signaling and reduces NFκB-dependent transcription
of adhesion molecules: (A) Protein expression of TRAF6 and key proteins in the activation of NFκB
signaling. q-PCR analysis of TRAF6, VCAM1 and ICAM1 gene expression in (B) KMS-11 TRAF6
knockdown (shTRAF6) and non-targeting control (NTC) cells, (C) U266 shTRAF6 and NTC cells,
(D) HS-5 cells co-cultured with KMS-11 NTC or shTRAF6 cells and (E) HS-5 cells co-cultured with U266
NTC or shTRAF6 cells. The data is presented as mean (± st. dev) of three independent experiments.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
3.4. TRAF6 Knockdown Augments the Effect of Bortezomib i Stromal Co-Cultures
Co-culture of MM cell lines with stromal cells attenuates the sensitivity of MM cells to therapeutic
agents [24]. We evaluated the effect of the proteasome inhibitor bortezomib on TRAF6 knockdown cells
compared to control cells when co-cultured with HS-5 cells. Knockdown of TRAF6 in combination with
bortezomib resulted in a significant decrease in viability of both KMS-11 (Figure 4A; p≤ 0.33) and U266
cells (Figure 4B; p≤ 0.24), compared to the effect of bortezomib in control cells, suggesting that targeting
of this E3 ligase could help to overcome stromal cell-induced protection against therapeutic agents.
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shTRAF6 cells co-cultured with HS-5. The data is presented as mean (±st. dev) of three independent
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4. Discussion
Adherence of MM cells to BMSCs activates signalling pathways that promote the growth, survival
and drug resistance of MM cells. Activation of the NFκB pathway, in particular, is central to the
pathogenesis of MM [25]. The E3 ligase TRAF6 is a key medi tor of NFκB ctivation and has previously
been highlighte as a potential therapeutic target in MM [19,20,22].
A recent study f und that BMSCs can induce TRAF6 expression n MM cells [22]. In ccordance
with th s, we d monstrate the increased expression of TRAF6 when MM cells are co-cultured with
BMSCs. W also found that there is a reciprocal in rease in TRAF6 expression in stromal cells upon
adherence of MM cell lines. Conversely, we ob erve a decrease in TRAF6 xpression in BMSCs
co-cultured with TRAF6 knockdown MM ell lines compared to control c ll . As the intera tion of
MM and BMSCs activates NFκB signalling in both the malignant plasma cells and in tr mal cells [26],
this suggests that TRAF6 may mediate NFκB s gnalling in both cell types. Consis ent with a number
of studies [19,22], we found that knockdown of TRAF6 reduced the proliferation of MM cell lines and
we demonstrate that this effect was most pronounced when MM cell lines were grown in co-culture
with stromal cells. To identify the upstream molecules important for TRAF6 activation in MM cells,
we used inhibitory peptides to disrupt TRAF6 interactions with either CD40 or RANKL. Inhibition of
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TRAF6-CD40 or TRAF6-RANKL did not significantly affect the growth of MM cell lines cultured alone
or in co-culture with stromal cells, suggesting that either other upstream signalling factors may be
more important or that a combination of factors is involved in TRAF6 signalling pathways in MM.
NFκB is comprised of heterodimers of the Rel family of transcription factors that commonly
exists as a dimer of p65 and p50 subunits. Inactive NFκB is sequestered in the cytoplasm bound to its
inhibitor IκBα and can be activated through a diverse range of stimuli [27]. TRAF6-mediated activation
of NFκB results from K63-linked polyubiquitin of TRAF6 itself and other TRAF6 substrates, leading to
recruitment of the TAK1 kinase and subsequent phosphorylation and activation of the IKK complex
(composed of IKKα and IKKβ) [11]. IKK α/β, in turn, phosphorylates IκBα, promoting its degradation
through the proteasome and freeing NFκB to locate to the nucleus and initiate transcription. Here,
we show that knockdown of TRAF6 blocks the phosphorylation of IKK in MM cells lines which
subsequently blocks phosphorylation of IκBα and p65.
NFκB induces the expression of adhesion molecules VCAM1 and ICAM1 on both MM and
BMSCs [23]. As TRAF6 knockdown inhibits NFκB signalling in MM, we hypothesised that it would
also affect the adhesive properties of MM cells. Looking first at the effect of TRAF6 knockdown on
semi-adherent cell line KMS-11, we found a significant reduction in the proportion of adherent cells in
TRAF6 knockdown cells. Furthermore, we demonstrated that both KMS-11 and U266 cells displayed a
reduced ability to adhere to a stromal cell line and to BMSCs isolated from MM patients. The associated
decrease in the expression of NFκB target genes ICAM1 and VCAM1 in both MM cells and BMSCs,
suggests that TRAF6-mediated activation of NFκB signalling contributes to their upregulation and
promotes the adherence of MM cells to BMSCs. The elevated expression of adhesion molecules, ICAM1
and VCAM1, is associated with disease progression in MM [28]. The reduction in the expression of
these molecules on both MM cells and BMSCs following TRAF6 knockdown lends further weight to
the potential of TRAF6 as a therapeutic target in MM.
Silencing of TRAF6 has been reported to enhance the effect of bortezomib in MM [19] and acute
myeloid leukaemia/myelodysplastic syndrome [29]. Interactions with BMSCs are well documented
to protect MM cells from drug-induced apoptosis and to contribute to acquired resistance to
therapies [30–32]. With this is mind, we investigated the effect of TRAF6 knockdown in combination
with bortezomib in MM cell lines co-cultured with stromal cells. TRAF6 knockdown similarly enhanced
the effect of bortezomib in stromal cell co-cultures, suggesting that the combination of TRAF6 inhibition
with bortezomib could effectively target MM cells within the bone marrow microenvironment.
In MM, adhesion to BMSCs plays an important role in the growth and survival of tumour cells.
This study revealed that TRAF6 is important in mediating interactions and adherence to BMSCs. These
findings, taken together with previous studies reporting that TRAF6 inhibition reduced osteoclast
formation [19], demonstrate that inhibition of TRAF6 represents a promising approach to target not
only MM cells but also their BM microenvironment.
Author Contributions: Conceptualization, L.J.C. and J.M.; methodology, J.M. and R.M.; investigation, J.M., R.M.
and L.J.C.; writing—original draft preparation, J.M., R.M. and L.J.C.; writing—review and editing, J.M., R.M. and
L.J.C.
Funding: This research was supported by Leukaemia and Lymphoma Northern Ireland.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
BM Bone marrow
BMSC Bone marrow stromal cell
ICAM1 Intracellular adhesion molecule 1
MM Multiple Myeloma
NFκB Nuclear factor kappa B
TRAF6 Tumour necrosis factor receptor-associated factor 6
VCAM1 Vascular adhesion molecule 1
Int. J. Mol. Sci. 2019, 20, 702 9 of 10
References
1. Guerrero-Garcia, T.A.; Gandolfi, S.; Laubach, J.P.; Hideshima, T.; Chauhan, D.; Mitsiades, C.; Anderson, K.C.;
Richardson, P.G. The Power of Proteasome Inhibition in Multiple Myeloma. Expert Rev. Proteom. 2018, 15,
1033–1052. [CrossRef] [PubMed]
2. Holstein, S.A.; McCarthy, P.L. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and
Clinical Experience. Drugs 2017, 77, 505–520. [CrossRef] [PubMed]
3. Varga, C.; Maglio, M.; Ghobrial, I.M.; Richardson, P.G. Current use of Monoclonal Antibodies in the Treatment
of Multiple Myeloma. Br. J. Haematol. 2018, 181, 447–459. [CrossRef] [PubMed]
4. Guang, M.H.Z.; McCann, A.; Bianchi, G.; Zhang, L.; Dowling, P.; Bazou, D.; O’Gorman, P.; Anderson, K.C.
Overcoming Multiple Myeloma Drug Resistance in the Era of Cancer ‘Omics’. Leuk. Lymphoma 2018, 59,
542–561. [CrossRef] [PubMed]
5. Robak, P.; Drozdz, I.; Szemraj, J.; Robak, T. Drug Resistance in Multiple Myeloma. Cancer Treat. Rev. 2018, 70,
199–208. [CrossRef] [PubMed]
6. Urashima, M.; Chen, B.P.; Chen, S.; Pinkus, G.S.; Bronson, R.T.; Dedera, D.A.; Hoshi, Y.; Teoh, G.; Ogata, A.;
Treon, S.P.; et al. The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone
Marrow. Blood 1997, 90, 754–765. [PubMed]
7. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, T.A.; Anderson, K.C.
Multiple Myeloma Cell Adhesion-Induced Interleukin-6 Expression in Bone Marrow Stromal Cells Involves
Activation of NF-Kappa B. Blood 1996, 87, 1104–1112.
8. Michigami, T.; Shimizu, N.; Williams, P.J.; Niewolna, M.; Dallas, S.L.; Mundy, G.R.; Yoneda, T. Cell-Cell
Contact between Marrow Stromal Cells and Myeloma Cells Via VCAM-1 and Alpha(4)Beta(1)-Integrin
Enhances Production of Osteoclast-Stimulating Activity. Blood 2000, 96, 1953–1960.
9. Sezer, O.; Heider, U.; Zavrski, I.; Kuhne, C.A.; Hofbauer, L.C. RANK Ligand and Osteoprotegerin in Myeloma
Bone Disease. Blood 2003, 101, 2094–2098. [CrossRef]
10. Inoue, J.; Gohda, J.; Akiyama, T. Characteristics and Biological Functions of TRAF6. Adv. Exp. Med. Biol.
2007, 597, 72–79.
11. Deng, L.; Wang, C.; Spencer, E.; Yang, L.; Braun, A.; You, J.; Slaughter, C.; Pickart, C.; Chen, Z.J. Activation of
the IkappaB Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a
Unique Polyubiquitin Chain. Cell 2000, 103, 351–361. [CrossRef]
12. Fang, J.; Muto, T.; Kleppe, M.; Bolanos, L.C.; Hueneman, K.M.; Walker, C.S.; Sampson, L.; Wellendorf, A.M.;
Chetal, K.; Choi, K.; et al. TRAF6 Mediates Basal Activation of NF-kappaB Necessary for Hematopoietic
Stem Cell Homeostasis. Cell Rep. 2018, 22, 1250–1262. [CrossRef] [PubMed]
13. Xiao, F.; Wang, H.; Fu, X.; Li, Y.; Wu, Z. TRAF6 Promotes Myogenic Differentiation Via the TAK1/p38
Mitogen-Activated Protein Kinase and Akt Pathways. PLoS ONE 2012, 7, e34081. [CrossRef] [PubMed]
14. Hamidi, A.; Song, J.; Thakur, N.; Itoh, S.; Marcusson, A.; Bergh, A.; Heldin, C.H.; Landstrom, M. TGF-Beta
Promotes PI3K-AKT Signaling and Prostate Cancer Cell Migration through the TRAF6-Mediated Ubiquitylation
of p85alpha. Sci. Signal. 2017, 10, eaal4186. [CrossRef] [PubMed]
15. Hostager, B.S. Roles of TRAF6 in CD40 Signaling. Immunol. Res. 2007, 39, 105–114. [CrossRef] [PubMed]
16. Cao, Z.; Xiong, J.; Takeuchi, M.; Kurama, T.; Goeddel, D.V. TRAF6 is a Signal Transducer for Interleukin-1.
Nature 1996, 383, 443–446. [CrossRef] [PubMed]
17. Rong, Z.; Cheng, L.; Ren, Y.; Li, Z.; Li, Y.; Li, X.; Li, H.; Fu, X.Y.; Chang, Z. Interleukin-17F Signaling Requires
Ubiquitination of Interleukin-17 Receptor Via TRAF6. Cell. Signal. 2007, 19, 1514–1520. [CrossRef] [PubMed]
18. Mizukami, J.; Takaesu, G.; Akatsuka, H.; Sakurai, H.; Ninomiya-Tsuji, J.; Matsumoto, K.; Sakurai, N. Receptor
Activator of NF-kappaB Ligand (RANKL) Activates TAK1 Mitogen-Activated Protein Kinase Kinase Kinase
through a Signaling Complex Containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 2002, 22, 992–1000.
[CrossRef]
19. Chen, H.; Li, M.; Sanchez, E.; Wang, C.S.; Lee, T.; Soof, C.M.; Casas, C.E.; Cao, J.; Xie, C.; Udd, K.A.; et al.
Combined TRAF6 Targeting and Proteasome Blockade has Anti-Myeloma and Anti-Bone Resorptive Effects.
Mol. Cancer. Res. 2017, 15, 598–609. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 702 10 of 10
20. Chen, H.; Li, M.; Campbell, R.A.; Burkhardt, K.; Zhu, D.; Li, S.G.; Lee, H.J.; Wang, C.; Zeng, Z.;
Gordon, M.S.; et al. Interference with Nuclear Factor Kappa B and c-Jun NH2-Terminal Kinase Signaling by
TRAF6C Small Interfering RNA Inhibits Myeloma Cell Proliferation and Enhances Apoptosis. Oncogene
2006, 25, 6520–6527. [CrossRef]
21. Crawford, L.J.; Anderson, G.; Johnston, C.K.; Irvine, A.E. Identification of the APC/C Co-Factor FZR1 as a
Novel Therapeutic Target for Multiple Myeloma. Oncotarget 2016, 7, 70481–70493. [CrossRef] [PubMed]
22. Huang, H.; Sun, Z.; Wang, X.; Liu, X.; Na, W.; Xu, R.; Ding, R.; Liu, H. The Effect of Marrow Stromal Cells on
TRAF6 Expression Levels in Myeloma Cells. Oncol. Lett. 2017, 14, 1464–1470. [CrossRef] [PubMed]
23. Gupta, D.; Treon, S.P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.T.; Lin, B.; Lentzsch, S.; Davies, F.E.;
Chauhan, D.; et al. Adherence of Multiple Myeloma Cells to Bone Marrow Stromal Cells Upregulates
Vascular Endothelial Growth Factor Secretion: Therapeutic Applications. Leukemia 2001, 15, 1950–1961.
[CrossRef] [PubMed]
24. Misund, K.; Baranowska, K.A.; Holien, T.; Rampa, C.; Klein, D.C.; Borset, M.; Waage, A.; Sundan, A. A
Method for Measurement of Drug Sensitivity of Myeloma Cells Co-Cultured with Bone Marrow Stromal
Cells. J. Biomol. Screen. 2013, 18, 637–646. [CrossRef] [PubMed]
25. Roy, P.; Sarkar, U.A.; Basak, S. The NF-kappaB Activating Pathways in Multiple Myeloma. Biomedicines 2018,
6, 59. [CrossRef] [PubMed]
26. Podar, K.; Richardson, P.G.; Hideshima, T.; Chauhan, D.; Anderson, K.C. The Malignant Clone and the
Bone-Marrow Environment. Best Pract. Res. Clin. Haematol. 2007, 20, 597–612. [CrossRef] [PubMed]
27. Christian, F.; Smith, E.L.; Carmody, R.J. The Regulation of NF-kappaB Subunits by Phosphorylation. Cells
2016, 5, 12. [CrossRef] [PubMed]
28. Terpos, E.; Migkou, M.; Christoulas, D.; Gavriatopoulou, M.; Eleutherakis-Papaiakovou, E.; Kanellias, N.;
Iakovaki, M.; Panagiotidis, I.; Ziogas, D.C.; Fotiou, D.; et al. Increased Circulating VCAM-1 Correlates with
Advanced Disease and Poor Survival in Patients with Multiple Myeloma: Reduction by Post-Bortezomib
and Lenalidomide Treatment. Blood Cancer. J. 2016, 6, e428. [CrossRef] [PubMed]
29. Fang, J.; Rhyasen, G.; Bolanos, L.; Rasch, C.; Varney, M.; Wunderlich, M.; Goyama, S.; Jansen, G.; Cloos, J.;
Rigolino, C.; et al. Cytotoxic Effects of Bortezomib in Myelodysplastic syndrome/acute Myeloid Leukemia
Depend on Autophagy-Mediated Lysosomal Degradation of TRAF6 and Repression of PSMA1. Blood 2012,
120, 858–867. [CrossRef]
30. Murray, M.Y.; Auger, M.J.; Bowles, K.M. Overcoming Bortezomib Resistance in Multiple Myeloma.
Biochem. Soc. Trans. 2014, 42, 804–808. [CrossRef]
31. Manni, S.; Carrino, M.; Semenzato, G.; Piazza, F. Old and Young Actors Playing Novel Roles in the Drama of
Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. Int. J. Mol. Sci. 2018, 19,
1512. [CrossRef] [PubMed]
32. Di Marzo, L.; Desantis, V.; Solimando, A.G.; Ruggieri, S.; Annese, T.; Nico, B.; Fumarulo, R.; Vacca, A.;
Frassanito, M.A. Microenvironment Drug Resistance in Multiple Myeloma: Emerging New Players.
Oncotarget 2016, 7, 60698–60711. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
